Fig. 6

ATF4 inhibition and prochlorperazine (PCZ) improve anti-PD1 therapeutic efficacy. a Liver images of the ATF4-stable knockdown HCC mouse model tumors treated with anti-PD1 therapy. (n = 4/group). b Liver images (scale bar, 1 cm), in vivo fluorescence imaging and liver sections (scale bar, 200 μm) of the tumors treated with PCZ or anti-PD1 therapy. c, d Quantification of in vivo fluorescence imaging signal value c and tumor volume size d (n = 5/group). e Western blot for CD48 expression in the tumors treated with PCZ. f GZMB⁺ CD8⁺ T cells in tumors following PCZ or anti-PD1 therapy were measured by flow cytometry. Quantification for flow cytometry in below. (n = 5/group). g CD8⁺ T cells in tumors following PCZ or anti-PD1 therapy were measured by flow cytometry. h Quantification for flow cytometry. (n = 5/group). i IHC of GZMB in tumors following PCZ or anti-PD1 therapy. Quantification is shown on the right. (n = 5/group). Statistical analysis performed using two-tailed t-test. ns for P > 0.05, *for P < 0.05, **for P < 0.01, ***for P < 0.001, ****for P < 0.0001